Compare · KYMR vs RVMD
KYMR vs RVMD
Side-by-side comparison of Kymera Therapeutics Inc. (KYMR) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KYMR and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $40.57B, about 4.5x KYMR ($8.99B).
- Over the past year, KYMR is up 75.1% and RVMD is up 229.0% - RVMD leads by 154.0 points.
- RVMD has been more active in the news (12 items in the past 4 weeks vs 2 for KYMR).
- Both have 25 recent analyst ratings on file.
- Company
- Kymera Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- $104.71-3.10%
- $178.07-5.91%
- Market cap
- $8.99B
- $40.57B
- 1M return
- -11.64%
- -9.54%
- 1Y return
- +75.07%
- +229.03%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 2
- 12
- Recent ratings
- 25
- 25
Kymera Therapeutics Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest KYMR
- Raymond James initiated coverage on Kymera Therapeutics with a new price target
- Chief Executive Officer Mainolfi Nello exercised 30,000 shares at a strike of $2.08 and sold $3,413,917 worth of shares (30,000 units at $113.80) as part of a pre-agreed trading plan (SEC Form 4)
- Kymera Therapeutics upgraded by Wolfe Research with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.
- Chief Legal Officer Adams Brian sold $744,297 worth of shares (6,371 units at $116.83), decreasing direct ownership by 11% to 50,254 units (SEC Form 4) to cover withholding tax
- SEC Form 144 filed by Kymera Therapeutics Inc.
- SEC Form 144 filed by Kymera Therapeutics Inc.
- Kymera Therapeutics to Participate in Upcoming September Investor Conferences
- Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
- Amendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.
Latest RVMD
- William Blair initiated coverage on Revolution Medicines
- Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- SEC Form 8-K filed by Revolution Medicines Inc.
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
- Chief Development Officer Sandler Alan B. exercised 6,000 shares at a strike of $58.84 and sold $1,275,294 worth of shares (6,309 units at $202.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.58% to 52,559 units (SEC Form 4)
- SVP & General Counsel Cislini Jeff sold $158,600 worth of shares (765 units at $207.32) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 51,776 units (SEC Form 4)
- Officer Mancini Anthony sold $743,285 worth of shares (3,708 units at $200.45) as part of a pre-agreed trading plan and exercised 3,121 shares at a strike of $33.62, decreasing direct ownership by 1% to 39,765 units (SEC Form 4)
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- Director Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)